Market Overview:
The global Iopamidol Injection market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of chronic diseases, rising demand for minimally invasive surgeries, and technological advancements in medical devices. By type, the 9 g I/ 30 mL segment is expected to account for the largest share of the global market in 2018, while by application, hospitals are expected to account for the largest share of the global market in 2018. Geographically, North America is estimated to dominate the global Iopamidol Injection market in 2018 followed by Europe and Asia Pacific.
Product Definition:
Iopamidol Injection is a type of radiocontrast agent used during medical procedures such as CT scans and MRIs. It helps to improve the clarity of images by making it easier to see the different tissues and organs within the body. Iopamidol Injection is important for accurate diagnosis and treatment planning.
9 g I/ 30 mL:
9 g I/ 30 mL is the standard injection volume for mid-to long-term treatment of migraine. It has been established as an adequate therapeutic dose based on both clinical and experimental data. The current guidelines of the American Headache Society (AHS) recommend a total dose of 45 - 60 mg/ 3 - 4 mL for acute attack management, which includes a loading dose (90 mg) followed by 2 - 3 maintenance doses (45 to 60 mg).
11.1 g I/ 30 mL:
11.1 g I/ 30 mL is a colorless solution of hydrogen peroxide used as an additive in Iopamidol Injection for the treatment of urological disorders such as urinary retention, cystitis, and benign prostatic hyperplasia.
Application Insights:
The global market is segmented by application into hospitals and clinics. Hospitals held the largest share of over 70.0% in 2017 owing to the availability of advanced healthcare facilities and services at a lower cost, which has resulted in I/ O units preferring hospital settings for injections. On average, hospitals have around 10 different types of iopamidol syringes ranging from 11 g to 0.5 cc available for various procedures thus making it convenient for patients to choose their preferred injection site based on their requirements and preferences without consulting a doctor first hand or getting an appointment at a hospital or clinic as most people prefer going directly to the place where medical emergencies are addressed thus resulting in higher adoption rates among both private as well as public health facilities worldwide thereby contributing towards higher market penetration rates across all regions globally over recent years due primarily but not exclusively towards its usage within Intensified-care Units (ICUs) & critical care units (CCUs).
Regional Analysis:
North America dominated the global market in 2017. The presence of well-established healthcare facilities and increasing prevalence of kidney diseases are some major factors responsible for its largest share. Moreover, the local presence of key manufacturers is expected to further boost revenue growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising medical tourism and improving healthcare infrastructure in emerging countries such as China, India, Thailand, Malaysia & Singapore. Furthermore, an increase in government initiatives aimed at reducing chronic disease burden will also support regional expansion over next eight years. For instance; In November 2016 ‘GlaxoSmithKline (GSK) Donation Program’ was launched by GSK which allowed it to donate medicines free of cost for public use in countries with limited access or no access due to political reasons or civil unrest (GSK).
Growth Factors:
- Increasing incidence of cancer: Iopamidol injection is used as a contrast agent in computed tomography (CT) scans and magnetic resonance imaging (MRI) scans to help diagnose and treat cancer. The increasing incidence of cancer is expected to drive the demand for iopamidol injection.
- Technological advancements: The introduction of new technologies such as positron emission tomography (PET) scan that use radioactive tracers has increased the demand for iopamidol injection.
- Rising awareness about early diagnosis and treatment: There is an increasing awareness among people about the benefits of early diagnosis and treatment, which is expected to drive the demand for iopamidol injection market during the forecast period.
- Growing number of hospitals and diagnostic centers: The growing number of hospitals and diagnostic centers across the globe is anticipated to boost growth in this market during the forecast period 2017-2025.. This will create opportunities for players operating in this market space.. 5 Emerging economies offer potential growth opportunities: A large population base coupled with rising income levels offers potential growth opportunities for players operating in this market space
Scope Of The Report
Report Attributes
Report Details
Report Title
Iopamidol Injection Market Research Report
By Type
9 g I/ 30 mL, 11.1 g I/ 30 mL, Others
By Application
Hospitals, Clinics
By Companies
Bracco Imaging, Sanochemia, Consentis, T2Pharma, Bayer, Takeda, Fuji Pharma, Hikari Pharmaceutical, BeiLu Pharma, Bracco Imaging
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
135
Number of Tables & Figures
95
Customization Available
Yes, the report can be customized as per your need.
Global Iopamidol Injection Market Report Segments:
The global Iopamidol Injection market is segmented on the basis of:
Types
9 g I/ 30 mL, 11.1 g I/ 30 mL, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bracco Imaging
- Sanochemia
- Consentis
- T2Pharma
- Bayer
- Takeda
- Fuji Pharma
- Hikari Pharmaceutical
- BeiLu Pharma
- Bracco Imaging
Highlights of The Iopamidol Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 9 g I/ 30 mL
- 11.1 g I/ 30 mL
- Others
- By Application:
- Hospitals
- Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Iopamidol Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Iopamidol injection is a medication used to relieve pain. It is a synthetic opioid that works by blocking nerve impulses.
Some of the key players operating in the iopamidol injection market are Bracco Imaging, Sanochemia, Consentis, T2Pharma, Bayer, Takeda, Fuji Pharma, Hikari Pharmaceutical, BeiLu Pharma, Bracco Imaging.
The iopamidol injection market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Iopamidol Injection Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Iopamidol Injection Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Iopamidol Injection Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Iopamidol Injection Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Iopamidol Injection Market Size & Forecast, 2018-2028
4.5.1 Iopamidol Injection Market Size and Y-o-Y Growth
4.5.2 Iopamidol Injection Market Absolute $ Opportunity
Chapter 5 Global Iopamidol Injection Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Iopamidol Injection Market Size Forecast by Type
5.2.1 9 g I/ 30 mL
5.2.2 11.1 g I/ 30 mL
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Iopamidol Injection Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Iopamidol Injection Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Iopamidol Injection Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Iopamidol Injection Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Iopamidol Injection Analysis and Forecast
9.1 Introduction
9.2 North America Iopamidol Injection Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Iopamidol Injection Market Size Forecast by Type
9.6.1 9 g I/ 30 mL
9.6.2 11.1 g I/ 30 mL
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Iopamidol Injection Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Iopamidol Injection Analysis and Forecast
10.1 Introduction
10.2 Europe Iopamidol Injection Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Iopamidol Injection Market Size Forecast by Type
10.6.1 9 g I/ 30 mL
10.6.2 11.1 g I/ 30 mL
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Iopamidol Injection Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Iopamidol Injection Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Iopamidol Injection Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Iopamidol Injection Market Size Forecast by Type
11.6.1 9 g I/ 30 mL
11.6.2 11.1 g I/ 30 mL
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Iopamidol Injection Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Iopamidol Injection Analysis and Forecast
12.1 Introduction
12.2 Latin America Iopamidol Injection Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Iopamidol Injection Market Size Forecast by Type
12.6.1 9 g I/ 30 mL
12.6.2 11.1 g I/ 30 mL
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Iopamidol Injection Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Iopamidol Injection Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Iopamidol Injection Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Iopamidol Injection Market Size Forecast by Type
13.6.1 9 g I/ 30 mL
13.6.2 11.1 g I/ 30 mL
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Iopamidol Injection Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Iopamidol Injection Market: Competitive Dashboard
14.2 Global Iopamidol Injection Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bracco Imaging
14.3.2 Sanochemia
14.3.3 Consentis
14.3.4 T2Pharma
14.3.5 Bayer
14.3.6 Takeda
14.3.7 Fuji Pharma
14.3.8 Hikari Pharmaceutical
14.3.9 BeiLu Pharma
14.3.10 Bracco Imaging
